| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Evolus, Inc. Common Stock$6.52
-0.2 (-3.03%)
C 42Pipeline Score Overvalued Pharma · Commercial
Market Cap
401.06 M
EPS
-0.67
P/E Ratio
-
Value Trade
2.99 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
73.14 M
R&D Expenses
2.24 M
Operating CF
-9.95 M
Total Assets
220.65 M
Total Liabilities
249.43 M
Equity
-28.78 M
D/E Ratio
12,345
-5.73 %
Week
22.54 %
1 Month
38.41 %
3 Month
-7.16 %
6 Month
-35.76 %
5 Year
-45.87 %
All Time
Cash Data
Cash Position
49.79 M
Monthly Burn
3.32 M
Runway
12.7 mo
Burn Trend
StableSEC Filing
May 4, 2026
Overview
Volume
1.32 M
52 Week Range
3.86 - 10.62
% held by Insiders
15.66 %
% held by Institutions
66.04 %
Enterprise Value
516.17 M
Total Shares
65.84 M
Short %
10.84 %
Float Shares
52.47 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Evolus, Inc. Common Stock
247Total events
6Upcoming
62Tier-1 (high impact)
2018 – 2028Coverage
Upcoming catalysts 2
TBD
T2Other Regulator Milestone
Subscribe to view catalyst details
TBD
T1FDA Approval
Subscribe to view catalyst details
Event history 2
TBD
▲Partnership / LicenseProfhiloCorporate
Subscribe to view catalyst details
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2019-02-01 | Jeuveau (prabotulinumtoxina-xvfs) | PDUFA Date | PDUFA | Approved | – | – | – |
2019-02-01 | Jeuveau (prabotulinumtoxina-xvfs) | PDUFA Date | PDUFA | Approved | – | – | – |
2019-02-01 | Jeuveau (prabotulinumtoxina-xvfs) | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
C42
Pipeline Score $187M
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.5x
rNPV / MCap Top 62%
Micro Cap (rank 348 of 912)
Percentile RankEvolus, Inc. Common Stock carries a moderate pipeline score (42/100), with $1.8B risk-adjusted pipeline value, led by PrabotulinumtoxinA-Xvfs in Skin Aging (Phase 1), across $83B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PrabotulinumtoxinA-Xvfs Small molecule | Glabellar Frown Lines | Phase 2 | NCT05320393 | 27% | $828M | COMPLETED | 154 | - | - | May 22, 2023 | - | Sep 4, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Jeuveau | — | Phase 2 | 2023-11-07 | The Phase II clinical trial of Jeuveau's extra-strength 40U formulation demonstrated effects lasting 26 weeks, indicating a significant duration of efficacy for the treatment of glabellar lines, as presented at the 2023 ASDS Annual Meeting. Read More | Document Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau Record Quarterly Net Revenue of $50 Million for Q3 2023, Up 48% from Q3 2022 Raises Full Read More | |
Jeuveau | — | Phase 2 | 2023-11-07 | The Phase II clinical trial of Jeuveau's extra-strength 40U formulation demonstrated effects lasting 26 weeks, indicating a significant duration of efficacy for the treatment of glabellar lines, as presented at the 2023 ASDS Annual Meeting. Read More | Document Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau Record Quarterly Net Revenue of $50 Million for Q3 2023, Up 48% from Q3 2022 Raises Full Read More | |
Jeuveau | — | Phase 2 | 2023-11-07 | The Phase II clinical trial of Jeuveau's extra-strength 40U formulation demonstrated effects lasting 26 weeks, indicating a significant duration of efficacy for the treatment of glabellar lines, as presented at the 2023 ASDS Annual Meeting. Read More | Document Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau Record Quarterly Net Revenue of $50 Million for Q3 2023, Up 48% from Q3 2022 Raises Full Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EOLS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
EOLS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
EOLS▼ -3%today
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. has announced the grant of 115,000 restricted stock units to 38 newly hired non-executive employees between April and July 2026. This initiative, approved by the company's compensation committee, is part of Evolus' 2023 Inducement Incentive Plan, aimed at enhancing its aesthetic portfolio. The move reflects the company's growth strategy and commitment to its workforce.
Read more →EOLSEvolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
Evolus, Inc. has announced a partnership with IBSA to exclusively develop and commercialize Profhilo® in the United States. This injectable is recognized as a market leader in Europe for improving skin quality. The collaboration aims to enhance Evolus's aesthetic product offerings and expand its market reach in the U.S.
Read more →EOLSEvolus to Participate in The Jefferies Global Healthcare Conference
Evolus is set to participate in the Jefferies Global Healthcare Conference. The event will provide a platform for the company to discuss its strategies and developments in the healthcare sector. Further details about the conference and Evolus's specific agenda have not been disclosed.
Read more →EOLSEvolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
Evolus has announced the commercial launch of its Estyme® Injectable Hyaluronic Acid Gels in Europe. This launch marks a significant expansion of the company's product offerings in the aesthetic market. The introduction of Estyme® aims to cater to the increasing demand for high-quality hyaluronic acid gels among consumers.
Read more →EOLSEvolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
Evolus has reported its financial results for the first quarter of 2026, highlighting a second consecutive quarter of positive adjusted EBITDA. The company remains optimistic and has reaffirmed its outlook for the full year, suggesting strong operational performance. This positive trend reflects the company's growth and financial stability.
Read more →EOLSDocument Evolus Reports First Quarter 2026 Financial Results Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook Global Net Revenue of $73.1 Million for the First Quart
Evolus, Inc. has announced its financial results for Q1 2026, highlighting a 7% increase in net revenue, totaling $73.1 million. The company achieved positive adjusted EBITDA for the second consecutive quarter, echoing the strength of its operating model, despite a GAAP loss of $6.8 million. Evolus continues to anticipate a full-year 2026 revenue guidance of $327 million to $337 million and plans to launch several new products. However, the company is now facing potential financial implications from a 15% tariff on products imported from South Korea.
Read more →EOLSEvolus to Report First Quarter Financial Results on May 4, 2026
Evolus has announced that it will report its first quarter financial results on May 4, 2026. This announcement is part of the company's regular financial reporting schedule. Investors and stakeholders are encouraged to tune in for the updates on the company's performance during this period.
Read more →EOLSEvolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
Evolus, Inc. will participate in the Needham 25th Annual Virtual Healthcare Conference, featuring a fireside chat and investor meetings. The chat is scheduled for April 14, 2026, at 3:45 PM ET, and will be accessible via their Investor Relations page. A replay will be available for 90 days post-event.
Read more →EOLSDocument Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability 1 Beginning in 2026 Total Net Revenue of $90.3 Mill
Evolus, Inc. reported strong financial results for 2025, achieving a total net revenue of $297.2 million, representing a 12% growth from the previous year. The company marked its sixth consecutive year of double-digit growth and anticipates sustainable profitability beginning in 2026 with revenue projections between $327 million and $337 million. The achievement of GAAP operating income in the fourth quarter highlights effective expense management. Evolus continues to enhance its market presence with a growing customer base and positive consumer engagement.
Read more →EOLSEvolus to Participate in The Leerink Partners Global Healthcare Conference
Evolus, Inc. will participate in the Leerink Partners Global Healthcare Conference in Miami, FL, with a fireside chat scheduled for March 11, 2026. Members of the management team will engage in discussions and investor meetings, showcasing the company's innovative approach in the aesthetic market. A replay of the chat will be available on their Investor Relations page.
Read more →EOLSEvolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
Evolus, Inc. will announce its fourth quarter and full-year 2025 financial results on March 3, 2026. The announcement will be followed by a conference call at 4:30 p.m. ET, where management will discuss the results and answer questions. The call will be accessible via phone and webcast.
Read more →EOLSEvolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
Evolus, Inc. announced preliminary unaudited net revenue results for Q4 and full-year 2025, highlighting six consecutive years of double-digit growth. The company anticipates profitability in Q4 2025 and provides guidance for 2026, emphasizing a return to market growth and continued international expansion. However, the results are preliminary and subject to change pending audit.
Read more →EOLSDocument Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue Provides 2026 Net Revenue Guidance and Maintains Projection for Full-Year 2026 Profitability 1 Preliminary Unaudited Net Reven
Evolus, Inc. has announced its preliminary unaudited net revenue results for Q4 and full-year 2025, highlighting significant growth. For Q4 2025, net revenues are estimated between $88.6 million and $90.6 million, representing a 12-15% increase year-on-year. The company also anticipates revenues for 2026 to grow by 11-13%, with plans for sustainable profitability starting in 2026. Additionally, Evolus has set long-term revenue expectations of $450 million to $500 million by 2028, showing confidence in its market strategy and product expansion efforts.
Read more →EOLS▲ +6.2%on this news
Document Evolus Reports Third Quarter 2025 Financial Results Total Net Revenue of $69.0 Million for Q3 2025, Up 13% from Q3 2024 Year-To-Date Growth of 10% Global Jeuveau Net Revenue of $63.2 Million for Q3 2025, Up from
Evolus, Inc. reported a strong financial performance for Q3 2025, posting total net revenues of $69.0 million, a 13% increase from Q3 2024. Sales from the Jeuveau product line accounted for $63.2 million, while the newly launched Evolysse filler contributed $5.7 million, marking a significant debut in the market. The company also projected achieving positive non-GAAP operating income between $5 million to $7 million in Q4 2025, positioning itself for sustainable annual profitability beginning in 2026. Despite these positives, the company faced a decline in cash reserves as proactive inventory purchases were made ahead of potential tariffs impacting their products.
Read more →EOLSDocument Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer
Evolus, Inc. has appointed Tatjana Mitchell as Chief Financial Officer, effective September 8, 2025. Ms. Mitchell has over 20 years of finance leadership experience across various industries, previously serving as Senior VP of Corporate Finance at Experian. Her track record includes driving revenue growth and managing large financial operations, which is expected to bolster Evolus's strategic objectives. As the company seeks to strengthen its position in the performance beauty market, Ms. Mitchell's leadership is anticipated to be instrumental in achieving growth and profitability.
Read more →EOLSDocument Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates Global Net Revenue of $69.4 Million for Q2 2025, Up 4% from Q2 2024 in a Market Where Overall U.S. Aesthetic Procedures Decrease
Evolus, Inc. reported its second quarter 2025 financial results, revealing a global net revenue of $69.4 million, a 4% increase from Q2 2024, despite a decline in U.S. aesthetic procedures. The successful launch of Evolysse contributed significantly to revenue and marks a strong entry into the market. However, the company faces challenges with a decrease in toxin demand due to weakened consumer sentiment. Evolus plans to optimize costs to achieve meaningful profitability by the end of 2025, with continued expansion of its product offerings.
Read more →EOLSDocument Evolus Announces Departure of its Chief Financial Officer
Evolus, Inc. announced the resignation of its Chief Financial Officer, Sandra Beaver, effective June 13, 2025. Beaver is leaving to join a private mental health and wellness technology company, and her departure is not related to any disagreements with Evolus. The company has initiated a search for her successor while maintaining operations through its experienced finance team. Evolus has recently launched a second product line and reported record revenues, positioning the company well for future success.
Read more →EOLSDocument Evolus Reports First Quarter 2025 Results Global Net Revenue of $68.5 Million for Q1 2025, Up 15.5% from Q1 2024 Meaningfully Outperformed Toxin Market Share Guidance Assumptions in Slower Market GAAP Operating
Evolus, Inc. reported its financial results for the first quarter of 2025, achieving a global net revenue of $68.5 million, a 15.5% increase compared to Q1 2024. The company noted a successful launch of its new product, Evolysse, which exceeded initial adoption expectations. Although the company reported a GAAP operating loss of $15.2 million, it reaffirms its net revenue guidance for the year, expecting to total between $345 million and $355 million. Notably, customer engagement metrics showed substantial growth, reflecting sustained demand for Jeuveau and the positive uptake of new offerings.
Read more →EOLSDocument Evolus Strengthens Balance Sheet with Refinancing Reducing Cost of Capital and Expanding Financial Flexibility Refinanced Existing Credit Facility Drawing $150 Million at Close with $100 Million of Strategic Inc
Evolus, Inc. announced a refinancing of its existing credit facility, increasing its capacity to $250 million. The new terms significantly lower the borrowing costs and enhance financial flexibility, allowing Evolus to avoid principal payments in 2026. The amended agreement was executed efficiently, maintaining a strong relationship with Pharmakon Advisors. This refinancing positions Evolus to support ongoing commercial initiatives and strategic initiatives effectively.
Read more →EOLSDocument Evolus Reports Record Fourth Quarter and Full Year 2024 Financial Results Reaffirms 2025 Guidance Global Net Revenue Record of $79.0 Million for the Fourth Quarter and $266.3 Million for the Full Year 2024, Repr
Evolus, Inc. reported strong financial results for the fourth quarter and full year of 2024, with net revenues reaching $79.0 million for Q4 and $266.3 million for the full year. These figures show significant growth over the previous year, with full-year profitability achieved earlier than expected. The company is set to launch Evolysse, a new line of injectable hyaluronic acid gels, in 2025 and anticipates continuing revenue growth. Overall, the company's focus on expanding its product offerings and maintaining strong consumer loyalty has contributed to its positive outlook.
Read more →EOLS▲ +28.3%on this news
Document Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance Expects U.S. Approval Within 90 Days for Evolysse Form and Evol
Evolus, Inc. announced preliminary unaudited net revenues for Q4 and full-year 2024, reporting significant growth. The company achieved $79 million in Q4 revenue and $266.3 million for the full year, both figures representing approximately 30% growth year-over-year. Evolus anticipates U.S. FDA approval within 90 days for its Evolysse product line, with a planned launch in Q2 2025. Looking ahead, Evolus is targeting net revenues between $345 million and $355 million for 2025, maintaining expectations for profitability.
Read more →EOLSDocument Evolus Reports Third Quarter 2024 Results Total Net Revenue of $61.1 Million for Q3 2024, Up 22% from Q3 2023 Year-To-Date Growth of 33% Received Approval for Estyme Injectable Hyaluronic Acid (HA) Gels in the E
Evolus reported third-quarter 2024 results with a total net revenue of $61.1 million, marking a 22% increase from the prior year. The company received approval for its Estyme injectable HA gels in the European Union, with a full launch planned for the second half of 2025. However, it also reported a loss from operations of $15.5 million for the quarter, up from $7.7 million in the previous quarter. Despite rising operational expenses, the company narrowed its full-year revenue guidance and reaffirmed its growth projections aiming for $700 million in revenue by 2028.
Read more →EOLSDocument Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance Total Net Revenue of $66.9 Million for Q2 2024, Up 36% from Q2 2023 Raises Full-Year 2024 Net Revenue Guidance to $260 Million to
Evolus, Inc. reported its financial results for Q2 2024, showcasing a total net revenue of $66.9 million, representing a 36% increase year-over-year. The company raised its full-year revenue guidance to between $260 million and $270 million, driven largely by its aesthetic product, Jeuveau. This quarter marked Evolus's first time achieving profitability, with a positive non-GAAP operating income of $1.1 million. Additionally, the company submitted PMA applications for new product lines, with anticipated product launches in 2025. Evolus continues to expand its market presence and aims for a revenue goal of $700 million by 2028.
Read more →EOLSDocument Evolus Announces Appointment of Albert G. White III to Board of Directors
Evolus, Inc. has announced the appointment of Albert G. White III as a member of its Board of Directors, effective July 1, 2024. Mr. White, the President and CEO of The Cooper Companies, brings extensive leadership experience and industry knowledge that is anticipated to support Evolus' growth strategy. His role will also include participation in Evolus' Compensation Committee. This addition to the board is aimed at helping Evolus transition from a single product to a multi-product company in the aesthetics market.
Read more →EOLSDocument Evolus Reports First Quarter 2024 Results and Provides Business Update Q1 2024 Net Revenue of $59.3 Million, Up 42% from Q1 2023 Non-GAAP Loss from Operations of $0.9 Million, on Track to Non-GAAP Profitability
Evolus, Inc. reported a strong performance in Q1 2024, with net revenues of $59.3 million, showing a 42% increase from the previous year. Despite a non-GAAP loss from operations of $0.9 million, the company is confident in achieving profitability by the fourth quarter of 2024 and the full year of 2025. The company also announced plans for FDA submissions of its new fillers within the next 90 days and reaffirmed its full-year revenue guidance of $255 million to $265 million. Evolus continues to expand its customer base and revenue goals, aiming for $700 million in total revenues by 2028.
Read more →EOLSDocument Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results Reaffirms 2024 Guidance Generated $0.8M of Cash from Operating Activities in Q4 2023 Recorded Lowest Quarter of Non-GAAP Operating Loss S
Evolus, Inc. reported significant financial achievements in Q4 and full year 2023, including a net revenue record of $61 million for Q4, reflecting a 40% increase year-over-year. The company also noted its lowest non-GAAP operating loss since inception, indicating improved efficiency. Looking forward, Evolus reaffirmed its revenue guidance of $255 to $265 million for 2024 and aims to achieve profitability by the end of 2024. Additionally, the business plans to expand its global presence with new product launches and markets targeted for growth.
Read more →EOLSDocument Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations Issues 2024 Guidance Preliminary Unaudited Net Revenue of Approximately $
Evolus, Inc. announced strong preliminary unaudited net revenue figures for the fourth quarter and full year of 2023, achieving approximately $61 million for Q4 and $202 million for the full year. This represents a 40% and 36% increase, respectively, over the prior year. The company also provided guidance projecting 2024 net revenues between $255 million and $265 million. Notable business developments include the expansion of their neurotoxin market share and growth in customer engagement, setting the stage for continued momentum into 2024.
Read more →EOLSDocument Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe Exclusive Distributor Agreement with Symatese Broadens Evolus' Dermal Filler Footprint Beyo
Evolus has signed an exclusive distribution agreement with Symatese to market next-generation dermal fillers in the U.K. and Europe, broadening its aesthetic product portfolio. The deal includes four unique fillers, expected to receive regulatory approvals in late 2024 with commercialization planned for 2025. Evolus has doubled its international market potential, and the agreement includes the issuance of shares to Symatese along with milestone payments. The company is confident in its growth strategy and believes the new products will drive topline revenue growth.
Read more →EOLSDocument Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau Record Quarterly Net Revenue of $50 Million for Q3 2023, Up 48% from Q3 2022 Raises Full
Evolus, Inc. reported significant financial growth in Q3 2023, achieving record net revenue of $50 million, marking a 48% year-over-year increase. The company raised its revenue guidance for the full year from $185-$195 million to $194-$198 million, supported by strong sales momentum and an expanding customer base. Notably, final Phase II clinical data presented at the American Society of Dermatologic Surgery Conference showed the efficacy of an 'Extra-Strength' formulation of Jeuveau with results lasting up to 26 weeks. Evolus remains focused on reaching profitability by 2025 while projecting robust growth in its aesthetic neurotoxin business.
Read more →EOLSDocument Evolus Reports Second Quarter 2023 Results and Provides Business Update Q2 2023 Net Revenue of $49.3 Million, Up 33% from Q2 2022 Raises Full-Year 2023 Net Revenue Guidance to $185 to $195 Million On Track to Ac
Evolus, Inc. reported strong financial results for Q2 2023, with net revenues up 33% to $49.3 million and an increase in full-year revenue guidance to between $185 million and $195 million. The company is seeing growth in customer accounts and repeat treatments, indicating strong brand loyalty. However, the operating loss grew due to higher expenses, prompting concerns about profit margins. Evolus remains focused on reaching sustained profitability by 2025 and expanding its market presence in Europe with its dermal fillers.
Read more →EOLS▲ +29.5%on this news
Document Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue Company Increases Full-Year 2023 Net Revenue Guidance to $185 to $195 Million Company Achieved Quarterly Net Revenue of $49.3 Millio
Evolus, Inc. reported a record revenue of $49.3 million for Q2 2023, marking a 33% year-over-year increase. The company has raised its full-year revenue guidance to between $185 million and $195 million due to accelerating growth, especially for its Jeuveau product. Key metrics also reported high enrollment in consumer loyalty programs and the acquisition of new customer accounts. CEO David Moatazedi expressed confidence in the company’s growth trajectory and future product expansions planned for 2025.
Read more →EOLSDocument Evolus Reports First Quarter 2023 Results and Provides Business Update Q1 2023 Net Revenue of $41.7 Million, Up 23% from Q1 2022 Reaffirms Full-Year 2023 Net Revenue Guidance of $180 to $190 Million Raises 2028
Evolus, Inc. reported its first quarter 2023 financial results, showing a 23% increase in net revenue, totaling $41.7 million. The company affirmed its full-year 2023 net revenue guidance of $180 to $190 million and raised its 2028 revenue forecast to $700 million, driven by the addition of the Evolysse dermal filler line. Additionally, Evolus noted a significant increase in customer engagement, with 60,000 new members in its loyalty program and over 600 new customer accounts added. The firm remains focused on achieving profitability while continuing to expand its market presence and product offerings.
Read more →EOLSDocument Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update Q4 2022 Net Revenue Reached an All-Time High of $43.6 Million, Up 26% from Q4 2021 Full-Year 2022 Net Revenue of $148.6 Milli
Evolus, Inc. announced its financial results for Q4 and full year 2022, reporting a record net revenue of $43.6 million for Q4, up 26% year-over-year. Total net revenues for the full year reached $148.6 million, reflecting strong demand and market share gains. The company reaffirmed its guidance for 2023, projecting revenues to reach between $180 million and $190 million. Evolus continues to focus on expanding its market presence internationally and enhancing its product offerings.
Read more →EOLS▲ +18.1%on this news· ran to +30% by day 3
Document Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau Nuceiva Revenue Aspiration Q4 2022 Preliminary Un
Evolus, Inc. has announced its preliminary unaudited net revenues for Q4 and full-year 2022, highlighting a growth of 26% and 49% respectively compared to previous periods. The company expects net revenue for 2023 to be between $180 million and $190 million, aiming for profitability by the end of the year. Additionally, Evolus has set an aspirational revenue target of $500 million by 2028, indicating strong market positioning and consumer adoption of its neurotoxin product, Jeuveau.
Read more →EOLS▲ +7.6%on this news
Document Evolus Extends Term of Credit Facility with Pharmakon Advisors Second Tranche of $50 Million Now Available Until
Evolus Extends Term of Credit Facility with Pharmakon Advisors Second Tranche of $50 Million Now Available Until December 31, 2023, Providing Continued Financial Flexibility All Other Facility Terms and Conditions Remain Unchanged Company Continues to Expect Existing Cash to
Read more →EOLSDocument Evolus Reports Third Quarter 2022 Results and Provides Business Update Reported Sales Up 27% to $33.9 Million Success of 'Switch Your Tox' Promotion Contributes to $3.5 Million Incremental Increase in Deferred R
Evolus Reports Third Quarter 2022 Results and Provides Business Update Reported Sales Up 27% to $33.9 Million Success of 'Switch Your Tox' Promotion Contributes to $3.5 Million Incremental Increase in Deferred Revenue Over Q2 and Understates Strength of Results 'Switch Your To
Read more →EOLSDocument Evolus Appoints Sandra Beaver as Chief Financial Officer
Evolus Appoints Sandra Beaver as Chief Financial Officer NEWPORT BEACH, Calif., August. 30, 2022 - Evolus, Inc. (NASDAQ EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, has named Sandra Beaver as its Chief Financia
Read more →EOLS▼ -17.6%on this news· ran to -28% by day 3
Document Evolus Reports Second Quarter 2022 Results and Provides Business Update Q2 2022 Net Revenue of $37.2 Million, Up 42% from Q2 2021 Reaffirms Full-Year 2022 Net Revenue Guidance of Upper End of $143 to $150 Millio
Evolus Reports Second Quarter 2022 Results and Provides Business Update Q2 2022 Net Revenue of $37.2 Million, Up 42% from Q2 2021 Reaffirms Full-Year 2022 Net Revenue Guidance of Upper End of $143 to $150 Million European Launch to Commence in Q3 2022 Strong Cash Position of
Read more →EOLSDocument Evolus Reports First Quarter 2022 Results and Provides Business Update Q1 2022 Net Revenue of $33.9 Million, Up 177% from Q1 2021 Now Guiding to Upper End of Full-Year 2022 Net Revenue of $143 to $150 Million Re
Evolus Reports First Quarter 2022 Results and Provides Business Update Q1 2022 Net Revenue of $33.9 Million, Up 177% from Q1 2021 Now Guiding to Upper End of Full-Year 2022 Net Revenue of $143 to $150 Million Reiterating Full-Year non-GAAP Operating Expense Guidance Strong C
Read more →EOLSDocument Evolus Announces Retirement of Chief Financial Officer Lauren Silvernail
Evolus Announces Retirement of Chief Financial Officer Lauren Silvernail NEWPORT BEACH, Calif., March 3, 2022 - Evolus, Inc. (NASDAQ EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that after nearl
Read more →EOLSDocument Evolus Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update Q4 2021 Net Revenue of $34.7 Million, Up 68% from Q4 2020 Full-Year 2021 Net Revenue of $99.7 Million, Up 76% Over 2020 Full-
Evolus Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update Q4 2021 Net Revenue of $34.7 Million, Up 68% from Q4 2020 Full-Year 2021 Net Revenue of $99.7 Million, Up 76% Over 2020 Full-Year 2022 Net Revenue Guidance of $143 to $150 Million Reaffirmed
Read more →EOLS▲ +17.3%on this news· ran to +32% by day 3
Document Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Net Revenue and Provides 2022 Guidance Q4 2021 Preliminary Unaudited Net Revenue of Approximately $34.7 Million, Up 68% from Q4 2020 Full-
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Net Revenue and Provides 2022 Guidance Q4 2021 Preliminary Unaudited Net Revenue of Approximately $34.7 Million, Up 68% from Q4 2020 Full-Year 2021 Preliminary Unaudited Net Revenue of Approximately $99.7
Read more →EOLSDocument Evolus Expands Board of Directors with Appointment of Digital and Beauty Innovator Brady Stewart
Evolus Expands Board of Directors with Appointment of Digital and Beauty Innovator Brady Stewart NEWPORT BEACH, Calif., January 5, 2022 - Evolus, Inc. (NASDAQ EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today
Read more →EOLSDocument Evolus Enters Into $125 Million Credit Facility with Pharmakon Advisors Initial Draw of $75 Million Expected to Fund Company Beyond Cash Flow Breakeven Second Draw of $50 Million Provides Financial Flexibility f
Evolus Enters Into $125 Million Credit Facility with Pharmakon Advisors Initial Draw of $75 Million Expected to Fund Company Beyond Cash Flow Breakeven Second Draw of $50 Million Provides Financial Flexibility for Potential Strategic Transactions NEWPORT BEACH, Calif., Decem
Read more →EOLSDocument Evolus Reports Third Quarter 2021 Results and Provides Business Update Record Quarter U.S. Net Revenue Grew 58% Year-over-Year to $26.7 Million $107.8 Million Cash Position at Quarter-End Initiated Jeuveau "Extr
Evolus Reports Third Quarter 2021 Results and Provides Business Update Record Quarter U.S. Net Revenue Grew 58% Year-over-Year to $26.7 Million $107.8 Million Cash Position at Quarter-End Initiated Jeuveau "Extra Strength" Phase II Clinical Program to Demonstrate Extended Dur
Read more →EOLSEvolus Reports Third Quarter 2021 Results and Provides Business Update
Record Quarter: U.S. Net Revenue Grew 58% Year-over-Year to $26.7 Million $107.8 Million Cash Position at Quarter-End Initiated Jeuveau® “Extra Strength” Phase II Clinical Program to Demonstrate Extended Duration NEWPORT BEACH, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Evolus,
Read more →EOLSDocument Evolus Reports Second Quarter 2021 Results and Provides Business Update Record Quarter Net Revenue grew 235% Year-over-Year to $26.1 Million Exceeded Annualized Revenue Run Rate Goal of $100 Million Low Q2 Cash
Evolus Reports Second Quarter 2021 Results and Provides Business Update Record Quarter Net Revenue grew 235% Year-over-Year to $26.1 Million Exceeded Annualized Revenue Run Rate Goal of $100 Million Low Q2 Cash Burn Resulting in $131.7 Million Cash Position at Quarter-End On
Read more →EOLSEvolus Reports Second Quarter 2021 Results and Provides Business Update
Record Quarter: Net Revenue Grew 235% Year-over-Year to $26.1 Million Exceeded Annualized Revenue Run Rate Goal of $100 Million Low Q2 Cash Burn Resulting in $131.7 Million Cash Position at Quarter-End On Track for European Launch in Early 2022, a $470 Million Market1 NEWPORT
Read more →EOLSEvolus Reports First Quarter 2021 Results and Provides Business Update
Q1 2021 Net Revenues of $12.2 million, Despite Half-Quarter ITC Impact Full Resolution of International Trade Commission (ITC) Case Restructured Balance Sheet with March 31, 2021 Pro Forma Cash Position of $140 million1 On Track for a $100 million Annual Net Revenue Run Rate i
Read more →EOLSEvolus Announces Pricing of Public Offering of Common Stock
NEWPORT BEACH, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its public offering of 9,000,000 shares of its common stock at a public offering price of $9.50 per share, before underwriting discounts and commissions. The gross
Read more →EOLSEvolus Announces Proposed Public Offering of Common Stock
NEWPORT BEACH, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS) announced today that it has commenced a proposed underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. Evolus expects to grant the u
Read more →EOLSDocument Evolus Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update Q4 2020 Net Revenue $20.6 Million, Highest Net Revenue Quarter Since Launch of Jeuveau Pro Forma Cash Position of $57 Million
Evolus Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update Q4 2020 Net Revenue $20.6 Million, Highest Net Revenue Quarter Since Launch of Jeuveau Pro Forma Cash Position of $57 Million at December 31, 20201 Newport Beach, Calif., March 24, 2021 - Evo
Read more →EOLSEvolus Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update
Q4 2020 Net Revenue $20.6 Million, Highest Net Revenue Quarter Since Launch of Jeuveau® Pro Forma Cash Position of $57 Million at December 31, 20201 NEWPORT BEACH, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a custom
Read more →EOLSDocument Evolus Strengthens Balance Sheet Through A $25.5 Million Cash Infusion And Elimination of $127.4 Million of Debt and Milestone Payments Pro Forma Cash Position of $57 Million at
Evolus Strengthens Balance Sheet Through A $25.5 Million Cash Infusion And Elimination of $127.4 Million of Debt and Milestone Payments Pro Forma Cash Position of $57 Million at December 31, 20201 Newport Beach, Calif., March 23, 2021 - Evolus, Inc. (Nasdaq EOLS), a performance
Read more →EOLSEvolus Strengthens Balance Sheet Through a $25.5 Million Cash Infusion and Elimination of $127.4 Million of Debt and Milestone Payments
Pro Forma Cash Position of $57 Million at December 31, 20201 NEWPORT BEACH, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced several
Read more →EOLSDocument Evolus Announces Promotion of Crystal Muilenburg to Chief Marketing Officer Newport Beach, Calif.
Evolus Announces Promotion of Crystal Muilenburg to Chief Marketing Officer Newport Beach, Calif., February 26, 2021 - Evolus, Inc. (Nasdaq EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the promo
Read more →EOLSDocument Evolus Announces Preliminary, Unaudited, Fourth Quarter and Full Year 2020 Net Revenue Q4 2020 Net Revenue of $20.6 Million Increased 16% Over Q3 2020 Newport Beach, Calif.
Evolus Announces Preliminary, Unaudited, Fourth Quarter and Full Year 2020 Net Revenue Q4 2020 Net Revenue of $20.6 Million Increased 16% Over Q3 2020 Newport Beach, Calif., February 23, 2021 - Evolus, Inc. (NASDAQ EOLS) today announced its preliminary, unaudited, net revenues
Read more →EOLSDocument AbbVie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation NORTH CHICAGO, Ill., NEWPORT BEACH, Calif, SEOUL
AbbVie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation NORTH CHICAGO, Ill., NEWPORT BEACH, Calif, SEOUL, February 19, 2021 - AbbVie (NYSE ABBV), Evolus (NASDAQ EOLS) and Medytox announce settlement agreements to fully resolve all outstanding litigati
Read more →EOLSDocument Evolus Provides Update on United States International Trade Commission (ITC) Case Section 337 Violation Partially Affirmed by ITC Jeuveau Sales and Marketing Continue Under Bond All Options Under Review to Resol
Evolus Provides Update on United States International Trade Commission (ITC) Case Section 337 Violation Partially Affirmed by ITC Jeuveau Sales and Marketing Continue Under Bond All Options Under Review to Resolve Legal Dispute Newport Beach, Calif., December 16, 2020 - Evolu
Read more →EOLSEvolus Reports Third Quarter 2020 Results and Provides Business Update
Q3 2020 Net Revenue of $17.7 Million; 34 Percent Increase Over Q3 2019 Cash1 Position Increased Over Q2 2020 to $110.1 Million NEWPORT BEACH, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach foc
Read more →EOLSDocument Evolus Reports Third Quarter 2020 Results and Provides Business Update Q3 2020 Net Revenue of $17.7 Million 34 Percent Increase Over Q3 2019 Cash 1 Position Increased Over Q2 2020 to $110.1 Million Newport Beach
Evolus Reports Third Quarter 2020 Results and Provides Business Update Q3 2020 Net Revenue of $17.7 Million 34 Percent Increase Over Q3 2019 Cash1 Position Increased Over Q2 2020 to $110.1 Million Newport Beach, Calif., October 29, 2020 - Evolus, Inc. (Nasdaq EOLS), a performa
Read more →EOLSEvolus Reports Second Quarter 2020 Results and Provides Business Update
Q2 2020 Net Revenue $7.8 Million, Up from $2.3 Million in Q2 2019 $40 Million Convertible Note Financing Closed in July 2020 Pro Forma June 30, 2020 Cash1 Position of $124.8 Million NEWPORT BEACH, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a perform
Read more →EOLSDocument Evolus Reports Second Quarter 2020 Results and Provides Business Update Q2 2020 Net Revenue $7.8 Million, Up from $2.3 Million in Q2 2019 $40 Million Convertible Note Financing Closed in July 2020 Pro Forma
Evolus Reports Second Quarter 2020 Results and Provides Business Update Q2 2020 Net Revenue $7.8 Million, Up from $2.3 Million in Q2 2019 $40 Million Convertible Note Financing Closed in July 2020 Pro Forma June 30, 2020 Cash1 Position of $124.8 Million Newport Beach, Calif.,
Read more →EOLSEvolus Provides Update on International Trade Commission (ITC) Case
Evolus Provides Update on International Trade Commission (ITC) Case Commission to Review Case; Final Determination Targeted for November 2020 Jeuveau Launch and Product Supply Unaffected by Initial Determination Newport Beach, Calif., July 6, 2020 - Evolus, Inc. (NASDAQ: EOLS)
Read more →EOLSEvolus Reports First Quarter 2020 Results and Provides Business Update
NEWPORT BEACH, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the first quarter ended March 31, 2020 and provided
Read more →EOLSEvolus Reports Fourth Quarter and Full Year 2019 Results and Provides Business Update
Evolus Reports Fourth Quarter and Full Year 2019 Results and Provides Business Update Q4 2019 Net Revenue $19.5 Million, Up from $13.2 Million in Q3 2019 Jeuveau Achieved Number Three Unit Share Position in the U.S. in 20191 Launched EvoluxTM; Only Practice Loyalty Program to
Read more →EOLSEvolus Reports Third Quarter 2019 Financial Results and
Evolus Reports Third Quarter 2019 Financial Results and Provides Business Update Jeuveau Generated $13.2 Million in U.S. Net Revenue in Q3 2019; up from $2.3 Million in Q2 2019 J.E.T. Enrolled Accounts Drove 90% of Q3 Revenue Jeuveau Achieved Number Three Unit Share Position
Read more →EOLSEvolus Reports Third Quarter 2019 Financial Results and Provides Business Update
Jeuveau® Generated $13.2 Million in U.S. Net Revenue in Q3 2019; up from $2.3 Million in Q2 2019 J.E.T. Enrolled Accounts Drove 90% of Q3 Revenue Jeuveau® Achieved Number Three Unit Share Position in the U.S. for Q3 20191 Nuceiva™ Approved in the European Union and Launched in
Read more →EOLSEvolus Reports Second Quarter 2019 Financial Results
Evolus Reports Second Quarter 2019 Financial Results Launched Jeuveau in the United States on May 15 Jeuveau Experience Treatment (J.E.T.) Program Exceeds Expectations Generated $2.3 Million in Jeuveau Net Revenue in Q2 2019 Newport Beach, Calif., August 12, 2019 - Evolus, In
Read more →EOLSEvolus Expands Board of Directors with Appointment of Independent Directors
Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D. NEWPORT BEACH, Calif., July 15, 2019 - Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering br
Read more →EOLSEvolus Reports First Quarter 2019 Financial Results
Evolus Reports First Quarter 2019 Financial Results U.S. Sales Force Hired and Trained with U.S Launch of Jeuveau Imminent Newport Beach, Calif., April 30, 2019 - Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering br
Read more →EOLSEvolus Provides Regulatory Update on Nuceiva in the European Union
Evolus Provides Regulatory Update on Nuceiva in the European Union Newport Beach, Calif., April 1, 2019 - Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced it expects the Europe
Read more →EOLSProvides Non-Dilutive Financing and Increased Flexibility Ahead of Jeuveau U.S.
Evolus Secures $100 Million Senior Debt Facility with Oxford Finance LLC Provides Non-Dilutive Financing and Increased Flexibility Ahead of Jeuveau U.S. Launch Newport Beach, Calif., March 18, 2019 - Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-cent
Read more →EOLSEvolus Reports Fourth Quarter and Full Year 2018 Results
Received U.S. FDA Approval of Jeuveau™ on February 1, 2019 Majority of Sales Force Hired with Launch Planned in the Coming Weeks Hosting Investor & Analyst Day on May 8th, 2019 in New York, NY NEWPORT BEACH, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS
Read more →EOLSEvolus Reports Third Quarter 2018 Financial Results
Evolus Reports Third Quarter 2018 Financial Results - Within 90 Days of FDA PDUFA Action Date for DWP-450 - - Granted Marketing Approval for DWP-450 by Health Canada - - Conference Call Today at 4:30PM ET - Irvine, Calif., November 5, 2018 - Evolus, Inc. (NASDAQ: EOLS), a com
Read more →EOLSEvolus Expands Role of Chief Medical Officer Rui Avelar, MD with Appointment as Head of R&D
Evolus Expands Role of Chief Medical Officer Rui Avelar, MD with Appointment as Head of R&D Irvine, Calif., August 15, 2018 - Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today announced the appointment of Chief Medical Officer Rui Avelar, MD, as Head
Read more →EOLSEvolus, Inc. Announces Full Exercise and Closing of Underwriters’ Overallotment Option
IRVINE, Calif., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS) (“Evolus”) today announced that the underwriters of Evolus’ previously announced public offering that initially closed on July 23, 2018, have purchased an additional 600,000 shares of Evolus’ common sto
Read more →EOLSEvolus Reports Second Quarter 2018 Financial Results
Evolus Reports Second Quarter 2018 Financial Results Irvine, Calif., August 2, 2018 - Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today reported financial results for the second quarter ended June 30, 2018. Second Quarter 2018 and Recent Highlights:
Read more →EOLSEvolus, Inc. Announces Pricing of Public Offering of Common Stock
IRVINE, Calif., July 18, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq:EOLS) (“Evolus”) announced today the pricing of its public offering of 4,000,000 shares of common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions. The offer
Read more →EOLSEvolus, Inc.
Evolus, Inc. Announces Pricing of Public Offering of Common Stock Irvine, Calif., July 18, 2018 - Evolus, Inc. (Nasdaq: EOLS) ("Evolus") announced today the pricing of its public offering of 4,000,000 shares of common stock at a public offering price of $20.00 per share, before
Read more →EOLSEvolus, Inc. Announces Proposed Public Offering of Common Stock
IRVINE, Calif., July 16, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq:EOLS) (“Evolus”) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) and commenced a proposed underwritten public offering of 5,000,0
Read more →EOLSEvolus Appoints Veteran Healthcare Executive Lauren Silvernail as Chief Financial Officer and Executive Vice President, Corporate Development
Evolus Appoints Veteran Healthcare Executive Lauren Silvernail as Chief Financial Officer and Executive Vice President, Corporate Development Irvine, Calif., May 29 2018 - Evolus, Inc. (NASDAQ: EOLS) ("Evolus" or the "Company"), a premiere aesthetics company, today announced the
Read more →EOLSEvolus Announces Progress with DWP-450 Regulatory Submissions
Evolus Announces Progress with DWP-450 Regulatory Submissions FDA Issues Favorable EIR Letter Related to Manufacturing Facility Evolus Receives FDA Complete Response Letter with Comments Isolated to CMC Items Conference Call Scheduled for 8:30am ET / 5:30am PT Irvine, Calif.,
Read more →EOLSEvolus Reports First Quarter 2018 Financial Results
IRVINE, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus”), a lifestyle aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today reported financial results for the first quarter ended Marc
Read more →EOLSEvolus Appoints Allergan Aesthetics Head as President and Chief Executive Officer
Evolus Appoints Allergan Aesthetics Head as President and Chief Executive Officer David Moatazedi Has Proven and Extensive Track Record of Building Fast Growing Aesthetics Market Led Entire U.S. Aesthetics Portfolio Including Botox Cosmetic Irvine, Calif., May 7 2018 - Evolus,
Read more →EOLSEvolus Reports Fourth Quarter and Full Year 2017 Financial Results
IRVINE, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus” or the “Company”), a medical aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today reported financial results for the fourth
Read more →EOLSEvolus, Inc. Announces Pricing of Initial Public Offering of Common Stock Irvine, Calif.
Evolus, Inc. Announces Pricing of Initial Public Offering of Common Stock Irvine, Calif., February 7, 2018 - Evolus, Inc. ("Evolus"), a medical aesthetics company focused on providing physicians and their patients with expanded choices in aesthetic procedures and treatments, tod
Read more →Competitive Position
How EOLS ranks across every disease it competes inCompetitive Position is a premium feature
See how EOLS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial